Direct Oral Anticoagulants (DOACs) Market to Boost $102.36 Bn by 2034

Direct Oral Anticoagulants (DOACs) Market Companies, Growth and Shares

The global direct oral anticoagulants (DOACs) market was estimated at US$ 43.9 billion in 2023 and is projected to grow to US$ 102.36 billion by 2034, rising at a compound annual growth rate (CAGR) of 8% from 2024 to 2034. DOACs are in high demand due to their use as anticoagulation in various cardiovascular diseases.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

Direct oral anticoagulants, or DOACs, have rapidly emerged as appealing substitutes for the established anticoagulation standard of therapy, which includes vitamin K antagonists. A number of cardiovascular disorders can be prevented and treated using DOACs. In thromboembolic situations, DOACs have become the most popular therapeutic substitutes, offering patients and physicians safer, more convenient, and more effective treatment options. Clinicians must make more difficult judgments about the right drugs, therapy length, and use in particular patients as a result of DOACs' growing involvement.

Direct Oral Anticoagulants (DOACs) Market Trends

• In May 2023, an extra €30 million was successfully secured in a Series B2 investment round by VarmX, a biotech business that focuses on developing novel strategies for the reversal of anticoagulation.
• In November 2022, approximately 460,000 additional people have been taking anticoagulant medications since January 2022, and over 24 million prescriptions have been written for patients, averting an estimated 17,000 strokes and 4,000 fatalities.

Market Opportunity: Growing Cases of Cardiovascular Diseases

Despite improvements in disease prevention and treatment, cardiovascular diseases (CVDs) remain one of the top causes of death globally. The US economy is heavily impacted by NCDs, primarily CVDs, as the Centers for Disease Control and Prevention (CDC) noted in 2022. The healthcare system spends over $216 billion on NCDs, and the rising rate of workplace absenteeism and the resulting decreased productivity cost the US economy $147 billion. Healthcare expenses are severely impacted by thrombotic events in CVDs. The direct oral anticoagulants (DOACs) market is growing since anticoagulant usage is advised for the prevention of thrombotic events in a variety of cardiovascular conditions, such as stroke prevention in atrial fibrillation, therapy, and secondary prevention of acute coronary syndrome.

Market Challenge: Side Effects of DOACs

The direct oral anticoagulants (DOACs) market faces challenges due to the potential side effects of using DOACs. Like any drug, DOACs might have negative effects on certain persons. According to the patient information booklet that comes with your medication, various DOACs might have different adverse effects. Any anticoagulant may cause bleeding as a negative effect. Major bleeding is one of the more significant complications that can occur.

Regional Insights

North America Dominated the Direct Oral Anticoagulants (DOACs) Market in 2023.

The dominance of North America is due to various factors, including advanced healthcare infrastructure, government support, growing investments in pharmaceuticals, and innovation & investments by key market players. The two major countries that contribute to the market’s growth are the U.S. and Canada.

The U.S. dominated the direct oral anticoagulants (DOACs) market in North America. The rising incidence of cardiovascular disorders is the main cause of the increase. Governments and major industry participants are taking initiatives to address the prevalence of CVDs in the United States. It is estimated that the annual healthcare expenses of cardiovascular risk factors, adjusted for inflation in 2022 US dollars, will treble from $400 billion to $1344 billion between 2020 and 2050. It is anticipated that the yearly cost of healthcare for cardiovascular problems will nearly triple, from $393 billion to $1490 billion, and that productivity losses will rise by 54%, from $234 billion to $361 billion.

Asia Pacific is Expected to Grow at the Fastest Rate During the Forecast Period.

Asia Pacific is the largest region with a large population, which provides advantages by providing a large consumer base and a large manpower. The direct oral anticoagulants (DOACs) market is growing strongly in the region due to factors like innovation, investment in healthcare, and investments by international market players. Another major factor that contributes to the growth is the growing prevalence of CVDs in the region. Some of the countries that mainly contribute to the growth of the market include China and India. Japan, and South Korea.

There are an estimated 330 million CVD patients in China today, which includes 245 million cases of hypertension, 12.39 million cases of coronary heart disease, 8.9 million cases of heart failure, 5 million cases of pulmonary heart disease, 4.87 million cases of atrial fibrillation, 2.5 million cases of rheumatic heart disease, 2 million cases of congenital heart disease, 45.3 million cases of peripheral artery disease, and 13 million strokes.

The Government of India's Ministry of Health launched a public campaign on heart health in September 2023, today, World Heart Day. The campaign focuses on increasing awareness of the risk factors for hypertension, which can result in cardiovascular disease-related morbidity and early death. The government set the lofty goal of enrolling 75 million people with diabetes and hypertension in routine treatment by December 2025. It has already begun to show benefits and is billed as the largest primary healthcare initiative in the world. According to the National NCD Portal, 11 million people with diabetes and hypertension were receiving treatment as of August 2023.

Segmental Insights

By type, the oral factor Xa inhibitors segment dominated the direct oral anticoagulants (DOACs) market in 2023. Many nations have now approved new oral anticoagulants for certain clinical reasons that specifically block either thrombin (dabigatran etexilate) or factor Xa (rivaroxaban, apixaban). These medications, in contrast to warfarin, have a quick beginning of action and a broad therapeutic range. Therefore, coagulation monitoring is not necessary. In addition to being more cost-effective than current treatments, these agents have the potential to enhance clinical outcomes and are more convenient for both patients and healthcare professionals.

For instance,

• In February 2024, in nations that recognize the CE mark, Roche declared that it had introduced three new coagulation tests for the oral Factor Xa inhibitors: rivaroxaban, edoxaban, and apixaban.

By application, the atrial fibrillation segment held a significant share of the direct oral anticoagulants (DOACs) market in 2023. The most prevalent clinically relevant heart rhythm problem, atrial fibrillation (AF), is regarded as an epidemic of cardiovascular disease in the twenty-first century. According to projection studies, the number of people with AF is expected to increase to 15.9 million in America by 2050 and 17.9 million in Europe by 2060. Both North American and European recommendations advocate direct oral anticoagulants (DOACs) as the first-line treatment for atrial fibrillation patients in order to prevent ischemic stroke.

Recent Developments

• In June 2023, in partnership with two globally renowned patient advocacy groups, Anthos Therapeutics, a clinical-stage biotechnology company creating novel treatments for metabolic and cardiovascular disorders, released new data describing the effects of patient-relevant bleeding (PRB) on people taking anticoagulants.
• In March 2023, in partnership with Janssen Pharmaceuticals, Inc., one of Johnson & Johnson's Janssen Pharmaceutical Companies (Janssen), Bristol Myers Squibb announced the start of the Phase 3 Librexia program, which is investigating the oral factor XIa (FXIa) inhibitor (antithrombotic) milvexian.

Top Companies in the Direct Oral Anticoagulants (DOACs) Market

• GlaxoSmithKline
• Bayer AG
• Viatris
• Daiichi Sankyo
• Bristol Myers Squibb Co
• Accord Healthcare
• Teva Pharmaceutical
• Sandoz
• Boehringer Ingelheim
• Janssen Pharmaceuticals
• Ingelheim Pharmaceuticals Inc.
• Pab Organics Pvt. Ltd.
• Pfizer
• Mylan
• Apotex

Segments Covered in the Report

By Type

• Oral Factor Xa Inhibitors
• Direct Thrombin Inhibitors (DTIs)

By Application

• Atrial Fibrillation
• Deep Vein Thrombosis
• Pulmonary Embolism
• Other

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait